Suptavumab 30 mg/kg
R2222-RSV-1332
Phase 3 small_molecule completed
Quick answer
Suptavumab 30 mg/kg for Respiratory Syncytial Virus Infections is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Respiratory Syncytial Virus Infections
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed